Pulm Week 3 Flashcards
(272 cards)
1
Q
Pneumonia
A
inflammation of the parenchyma of the lung (alveoli) and accumulation of abnormal alveolar filling with fluid of lung tissue
2
Q
Physical exam findings of pneumonia
A
1) Fever, chills
2) SOB, tachypnea
3) crackles, rhonchi
4) evidence of consolidation (bronchial breath sounds, egophony dullness to percussion)
5) pleuritic chest pain
6) productive cough (bacterial) or unproductive (atypical, viral)
3
Q
Who should get blood and sputum cultures?
A
Get blood and sputum cultures for inpatients or patients with healthcare associated risk factors
-Treat out patients empirically and follow for improvement
4
Q
Pathogenesis of pneumonia
A
Most commonly caused by infection + inhalation of infectious particles or microaspiration
Pulmonary parenchymal inflammation due to infection (bacterial, fungal, viral) in which purulence develops and fills the alveoli
5
Q
Community acquired pneumonia (CAP)
A
begins outside hospital
- Diagnosed less than 48 hours after hospital admission
- Patient not a resident in long-term facility for > 14 days or more before onset of symptoms
6
Q
Hospital (Nosocomial) acquired pneumonia (HAP)
A
PNA > 48 hrs after hospital admission
7
Q
Ventilator associated pneumonia (VAP)
A
PNA > 48-72 hrs after endotracheal tube intubation
8
Q
Healthcare-associated pneumonia (HCAP)
A
PNA in a non-hospitalized patient with extensive healthcare contact
Hemodialysis, nursing home, IV therapy, wound care, IV chemo
9
Q
Typical bacteria that cause community acquired pneumonia (7)
A
1) Streptococcus Pneumoniae (30-60% of CAP)
2) Haemophilus influenzae
3) Moraxella catarrhalis
4) Staphylococcus aureus
5) Group A streptococci
6) Anaerobes
7) Aerobic gram-negative bacteria
10
Q
Atypical bacteria that cause community acquired pneumonia (3)
A
10-20% of CAP
1) Legionella species
2) Mycoplasma pneumoniae
3) Chlamydia pneumoniae
11
Q
Characteristics of HAP/VAP/HCAP Organisms
A
- Organisms that colonize the oropharynx
- Enter lower respiratory tract by micro or macro aspiration
- Frequently polymicrobial in origin
- Vary based on antimicrobial practices in hospital
- Tend to be multidrug resistant (MDR)
12
Q
Gram negative (5) and gram positive (1) pathogens that cause HAP/VAP/HCAP
A
Gram negative pathogens: “SPACE”
1) Serratia
2) Pseudomonas
3) Acinetobacter
4) Citrobacter
5) Enterobacter or Escherichia coli
Gram positive pathogens:
1) MRSA
13
Q
Outpatient treatment of CAP duration and abx (3)
A
5 day therapy
Macrolide (azithromycin) or Doxycycline
Respiratory fluoroquinolone (levofloxacin)
14
Q
Inpatient, Non-ICU treatment of CAP (2)
A
Respiratory fluoroquinolone
or
Beta-lactam + Macrolide
15
Q
Inpatient, ICU treatment of CAP (2)
A
Beta-lactam + Macrolide
or
Beta-lactam + Respiratory fluoroquinolone
Consider anti-MRSA therapy
16
Q
HCAP/VAP/HAP Treatment duration
A
7-8 day therapy (longer for pseudomonas/MRSA)
Critical to de-escalate therapy based on culture data and clinical response in 48-72 hours
17
Q
HCAP/VAP/HAP Treatment: ______ + _______ + ________
A
Antipseudomonal Agent:
1) Beta-Lactam + Beta-Lactamase inhibitor
2) 4th Gen Cephalosporin
3) Carbapenem
Plus 1 of the following:
1) Antipseudomonal fluoroquinolone
2) Anti-gram negative aminoglycoside
Plus 1 anti-MRSA medication:
1) Linezolid
2) Vancomycin
18
Q
Epidemiology of influenza
A
Distinct outbreaks every year, nearly every year
Begin abruptly over a 2-3 week prior and last 2-3 months
Usually infects 10-20% in general population and can exceed 50% in pandemics
19
Q
Transmission and incubation of influenza
A
close contact with infected individual via exposure to respiratory secretions
Incubation period 1-4 days, onset of illness within 3-4 days
Virus shed from infected individuals 24-48 hours prior to onset of illness and can continue for 10 days (longer in at risk populations)
20
Q
Pathogenesis of influenza
A
Hemagglutinin (surface glycoprotein) binds to sialic acid residues on respiratory epithelial cell surface glycoproteins and starts infection
→ viral replication, progeny virions bound to host cell membrane
→ Neuraminidase cleaves link between virion and host, and liberates new virions
21
Q
Influenza A
A
(H1,2,3 + N1,2) has more antigenic shift (major changes in glycoproteins)
Antigenic shift → epidemics and pandemics
22
Q
Influenza B
A
only has antigenic drifts (minor changes in glycoproteins)
Antigenic drift → localized outbreaks
23
Q
Clinical features of influenza infection
A
Abrupt onset of fever, headache, myalgias and malaise
Cough, nasal congestion, sore throat
Pharyngeal hyperemia, lymphadenopathy
24
Q
Complications associated with influenza infection (4)
A
Primary IFN Pneumonia
Secondary bacterial pneumonia
Myositis, rhabdomyolysis
CNS involvement
25
Treatment of influenza
Give within 48 hours of illness (neuraminidase inhibitors - oseltamivir, zanamivir)
26
Starling resistor model in upper airway collapse
1. P-upstream > P-downstream > P crit then there is no flow limit and tube will stay open
2. Pus > Pcrit> Pds → point of narrowing but not complete collapse
a. Physics of snoring
3. Pcrit > Pus > Pds → collapse of airway no matter what the pressure inside airway
a. Upstream pressure always > downstream pressure because you are taking a breath in
27
Effect of obesity on upper airway
fat deposition in tongue itself and neck → narrowing of oropharynx (only becomes a problem during sleep)
28
Effect of sleep on upper airway
lose a lot of protective mechanisms when you sleep (decreased tonic output, decreased output from inspiratory premotor neurons, and decreased reflex stimulation, higher threshold)
29
Defense against airway collapse (3)
1. Upper airway recruitment threshold: stimuli (intra-airway pressure becomes negative enough, increased CO2, decreased O2) recruit upper airway dilator muscles to adequately overcome Pcrit
a. Airway narrowing → increased resistance → increased muscular EMG activity
b. High upper airway recruitment threshold → increased duration of obstructive events
2. Arousal threshold: negative pressure needed in order to trigger arousal
a. Low arousal threshold → frequent arousals → hyperventilation → hypocapnia → decreased ventilation and upper airway muscle tone
3. Loop gain: magnitude of ventilatory response to stimuli
a. High loop gain → greater sensitivity to CO2 and O2 → hyperventilation → hypocapnia → decreased upper airway muscle tone
30
Prevalence of snoring in men and women
44% men 28% women
31
Prevalence of upper airway resistance syndrome
9% in population
32
Prevalence of sleep apnea syndrome
a. 4% of men, 2% of women
b. Obstructive: 85%
c. Mixed or Complex: 14%
d. Central: less than 1%
33
Cheyne-Stokes respiration
a. 40-50% of patients with heart failure
b. 10% of patients with stroke
c. Greater sensitivity to CO2 → hyperventilation and “overshooting” of PaCO2 below the apneic threshold → reduces drive to breathe
d. Arousals generally occur at peak of ventilation
34
Complications of sleep disordered breathing
primarily cardiovascular and motor vehicle crash
35
Clinical deatures of obstructive sleep apnea syndrome
1. More common in men and as they age until 60s or 70s
2. PMH: chronic rhinitis, acromegaly, neuromuscular disorder, amyloidosis, upper airway anatomic abnormalities, genetic syndromes (e.g. Downs)
3. Family History: first degree relative with OSA
4. Social history: smoking, alcohol, obesity
5. Medications: sedative-hypnotics, opioids
36
Symptoms of obstructive sleep apnea syndrome
excessive daytime sleepiness, snoring, memory loss, decreased concentration, decreased libido, irritability, attention deficit (children), hyperactivity (children), nocturia or enuresis
37
Diagnosis of obstructive sleep apnea
1. Epworth sleepiness scale
2. Physical Exam:
a. Mallampati classification - airway narrowing
b. Neck circumference > 17 inches (male) or > 16 inches (female) → greater risk
c. Retrognathia (recessive jaw) → decreases space inside mouth → tongue moves posteriorly and narrows airway diameter
3. Polysomnography (sleep study):
a. Full night (diagnostic only)
b. Split night (diagnostic and therapeutic)
c. Portable (diagnostic only)
i. Not for patients with confounding cardiopulmonary abnormalities
38
Treatment of obstructive sleep apnea (9)
1. general measures- sedative avoidance, smoking cessation
2. weight reduction
3. positional therapy
4. oxygen therapy
5. pharmacotherapy
6. PAP
7. Oral devices
8. Upper airway surgery
9. Nerve stimulation
39
Positive airway pressure (PAP)
Mechanical solution to mechanical problem
Helps patient to overcome critical airway pressure
40
Oral devices (2)
1. Tongue Retainer - holds tongue in anterior (forward) position
i. For patients with compromised dentition
2. Mandibular repositioner - advances mandible (and tongue) forward
i. Contraindications: compromised dentition, TMJ dysfunction
3. Billy's penis
41
Upper airway surgery for obstructive sleep apnea (4)
1. Tracheostomy: percutaneous tracheal opening distal to pharynx to bypass area of upper airway obstruction
i. Indicated for severe life-threatening OSA
2. Maxillomandibular advancement: advance both maxilla and mandible, enlarges retrolingual and retropalatal airway
i. Pain and nerve damage possible complications
ii. Effective up to 90% of the time
3. UvuloPalatoPharyngoPlasty (UPPP): excision of uvula, posterior soft palate, redundant pharyngeal tissue, and tonsils
i. Rarely effective - high recurrence of OSA
4. Tonsillectomy and adenoidectomy: remove tonsils and enlarged adenoids (best for children with OSA)
42
Nerve stimulation for OSA
Similar to a pacemaker - box connects to wire that goes to intercostal muscles and tongue
Breath initiated by patient and then box stimulates muscle contraction
43
Risk factors of lung cancer (8)
1) Smoking
2) Environmental risk factors (Second hand smoke, radon gas, asbestos, industrial, polycyclic aromatic hydrocarbons, air pollution, silica, vinyl chloride, TB)
3) COPD secondary to smoking
4) Family history
5) Gender - females > males
6) Sarcoidosis, ILD/pulmonary fibrosis (chronic inflammation)
7) Previous tobacco related cancer - lung cancer, head/neck cancer
8) Sputum cytologic atypia
44
Non-small cell lung cancer
87% of cases
1) Squamous cell carcinoma
2) Adenocarcinoma
3) Large Cell
45
Squamous cell carcinoma
| general info
25% of cases
| **strongly linked to smoking
46
Squamous cell carcinoma histopathology (3)
1) PROXIMAL/CENTRAL squamous metaplasia of bronchial epithelium
2) Usually >3 cm in diameter
3) Keratin pearls (stain + for keratin)
47
Squamous cell carcinoma (genetic mutations)
p53, Rb, p16
No proven genomically targeted therapies
48
Adenocarcinoma general info
40% of cases
**most common type in women and non smokers
**subclass is bronchioalveolar carcinoma, insitu
49
Adenocarcinoma histopathology (3)
1) PERIPHERAL cancer
2) Cells attempt to form gland like structure
3) stain + for mucin
50
Adenocarcinoma genetic mutations (3)
1) K-Ras
2) EGFR
3) EML-4-ALK
51
Large cell carcinoma
heterogenous group of poorly differentiated tumors, arise in distal airway epithelial cells
- Present as unresolving infiltrate or nodules
- does not stain for mucin or keratin
52
Small cell carcinoma general info
13% of cases
- highly aggressive
- strongly linked to smoking
- metastasizes widely (especially to brain)
- very bad prognosis
53
Small cell carcinoma histopathology (5)
1) small, dark staining cells that form clusters
2) stain + for neuroendocrine markers (NCAM)
3) often presents with hilar and mediastinal lymphadenopathy
4) Bronchial origin (can narrow/obstruct bronchi)
5) CENTRAL lesion
54
Characteristics that define solitary pulmonary nodules (5)
1) Lesion less than 3 cm diameter
2) Round or oval with smooth contour
3) Surrounded by aerated lung
4) No satellite lesions
5) No associated atelectasis, pneumonitis, or regional adenopathy
55
Goals of solitary pulmonary nodule evaluation (3)
1) Expedite resection of potentially curable lung cancer
2) Minimize resection of benign nodules
3) Morbidity and mortality of nodule evaluation is 5-10%
56
Evaluation of solitary pulmonary nodules
- Size of nodule, age, prior cancer history, smoking, COPD, asbestos
- Look at previous imaging (stable for > 2 yrs = no evaluation needed)
- Larger node and higher risk patient is more frequent CTs for screening
- All resections must include a lymph node dissection
57
Presenting symptoms of lung cancer
```
weight loss
cough (or change in chronic cough)
weakness
hemoptysis
pain (local or metastatic disease)
neuro symptoms/signs
lymphadenopathy
```
*Paraneoplastic symptoms (especially for small cell - ADH, ACTH release, hypercalcemia, gynecomastia)
58
Tests to diagnose lung cancer (5)
1) Blood tests: high alk phos (bone metastasis), high Ca2+, anemia, cytopenias suggest metastases
2) CT/PET scan (solitary pulmonary nodule is common finding)
3) Tissue study (transbronchial biopsy, open lung biopsy, needle biopsy)
4) Cytology
5) mediastinoscopy to assess mediastinal lymph nodes
59
Staging of small cell lung cancer
Limited disease (25-30%) - limited to ipsilateral hemithorax (including contralateral mediastinal nodes)
Extensive disease (70-75%) - tumor extends beyond hemithorax (including pleural effusions)
60
Staging of NSCLC
TMN staging
tumor size, nodal involvement, presence or absence of metastases
61
T0
Tis
T1a
T1b
T0 = no evidence of primary tumor
Tis = carcinoma in situ
T1a = tumor less than 2cm (not in mainstem bronchus)
T1b = tumor > 2-3 cm (not in mainstem bronchus)
62
T2a
| T2b
T2a = tumor less than 5 cm, or present in mainstem bronchus (not within 2 cm of carina, no invasion of visceral pleura, atelectasis, or pneumonitis)
T2b = tumor > 5-7 cm
63
T3
T4
T3 = tumor > 7 cm, or invades chest wall, diaphragm, mediastinal pleura, parietal pericardium, less than 2 cm from carina, associated with atelectasis or pneumonitis, or more than 2 malignant nodules in the same lobe
T4 = tumor of any size with invasion of mediastinum, heart, great vessels, trachea, esophagus, vertebral body, or carina + malignant nodules in ipsilateral lung
64
N0
N1
N2
N3
```
N0 = no nodal involvement
N1 = metastasis to ipsilateral peribronchial or hilar region
N2 = metastases to ipsilateral mediastinal and/or subcarinal lymph nodes
N3 = metastases to supraclavicular or contralateral mediastinal, hilar, or scalene nodes
```
65
M0
M1a
M1b
M0 = no distant metastases
M1a = separate tumor nodules in contralateral lobe, tumor with pleural nodules, or malignant pleural or pericardial effusion
M1b = distant metastasis
66
Genetic alterations in non-small cell lung cancer (4)
1) Epidermal Growth Factor (EGFR/ERB-1)
2) Her2/neu (ERG-2)
3) Vascular Endothelial Growth Factor (vEGF) over expressed
4) Ras mutations
67
Epidermal Growth Factor (EGFR) and treatment of EGFR NSCLC
50-80% NSCLC (most common in non smokers)
Overexpression of EGFR, associated with poor prognosis
Drugs available = erlotinib, gefitinib, cetuximab, afatinib
VERY expensive
Development of resistant tumor → must move down the line of treatments
68
Her2/neu (ERB-2) and treatment of Her2 NSCLC
10% NSCLC
| Drugs available = trastuzumab (herceptin)
69
Vascular Endothelial Growth Factor (vEGF) and treatment of vEGF NSCLC
Over expressed
Drugs available = bevacizumab (Avastin)
70
Ras mutations
2-30% NSCLC, adenocarcinoma
Associated with resistance to tyrosine kinase inhibitors (TKIs, EGFRi)
71
Hoarseness
abnormal voice changes, breathy, raspy, strained, weak
72
Dysphonia
general alteration of voice quality (usually laryngeal source)
73
Dysarthria
defect in rhythm, enunciation, articulation (usually neurological or muscular source)
74
Stridor
large airway noise from obstruction
75
Inspiratory vs. Expiratory vs. Biphasic stridor
Inspiratory → supraglottic, extrathoracic
E.g. epiglottitis, epiglottis cancer
Expiratory → tracheal, large bronchi intrathoracic
E.g. tracheal cancer
Biphasic → laryngeal, immediate subglottis
E.g. subglottic stenosis (due to intubation), laryngeal cancer, croup
76
Sertor
snoring sound from nose, nasopharynx, throat
77
Causes of hoarseness (top 2 plus a few others)
1) Viral laryngitis (acute) - most common cause
2) Laryngeal reflux (chronic)
Other: Vocal abuse, allergies, chronic cough, nodules, polyps, trauma, age, neuro disorders, smoking, malignancies of thyroid, larynx, lungs
78
When should a patient see an otolaryngologist?
Hoarseness lasts longer than 2-3 weeks
Hoarseness associated with:
- Pain (ear radiation?)
- Coughing up blood
- Difficulty swallowing
- Lump in neck
- Complete loss or severe change in voice lasting longer than a few days
79
5 layers of vocal folds
1) Epithelium
2) Superficial lamina propria
3) Intermediate lamina propria
4) Deep lamina propria
5) Vocalis muscle (medial thyroarytenoid)
80
Components of voice production (3)
1) Source (pulmonary/infraglottic)
2) Vibratory production (larynx/intrinsic muscles, extrinsic muscles)
3) Resonance (supraglottic and oral phase)
81
Components that generate source airflow
1) diaphragm
2) intercostal muscles
3) tracheobronchial tree, lungs, thorax
4) abdominal support system
82
Effect of ANS on voice
ANS plays role in mucus production, voice stability → B-blockers
Fine muscular control at risk with sympathetic stimulation or when a neurological conditions exists
83
Diaphragm and voice production
inspiratory force and fine regulation of singing
84
Abdominal muscles and voice production
maintains efficient, constant power source and inspiratory-expiratory mechanism
85
Extrinsic muscles and vibratory production
- maintain position of larynx and neck
- Essential to consistent sound
- Change in tension, position, tilt
- Changes resting length of intrinsic muscles
- Well trained singer can sing for hours
86
Cartilages of larynx (3)
Thyroid, cricoid (only one that is a complete ring), paired arytenoids
87
Intrinsic muscles of larynx and their function
arytenoid muscle (moves vocal folds)
posterior cricoarytenoid muscle (only muscle that opens your vocal folds)
As larynx descends pitch will drop (e.g. with puberty)
88
Supraglottic/oral phase and resonance
Includes supraglottic larynx lips, teeth, tongue, palate, pharynx, nasal cavity, and sinuses
- ALL shape the way your voice sounds
- Can tune our frequencies by changing shape of our vocal tract
- Vocal tract length effects frequencies → shorter tract = higher frequencies
89
Central innervation of vocal folds
Cerebral cortex:
- Speech area = temporal cortex
- Voice area = precentral gyrus
--> Vagus (X) exits medulla --> jugular foramen
→ superior laryngeal nerve (internal branch = sensation, external branch = motor to cricothyroid muscle)
→ *Recurrent laryngeal nerve (all intrinsic muscles but CT)
90
Major causes of hoarseness: (10)
1) Vocal nodules, cysts, and polyps
2) Granulomas
3) Reinke's edema
4) Vocal fold hemorrhage or tear
5) Presbyphonia and vocal bowing with age
6) Immobile vocal fold
7) Laryngopharyngeal reflux
8) Papilomas
9) Leukoplasia
10) Precancerous/cancerous lesions
91
Laryngopharyngeal Reflux
Escape of stomach acids from stomach into esophagus through laryngoesophageal sphincter
May reach larynx, oral cavity, and lungs
92
Symptoms of Laryngopharyngeal Reflux
hoarseness, chronic cough, foreign body sensation (globus), tracheal stenosis
Bad breath or bitter taste in a.m.
A.m hoarseness or after meals
Sensation of post nasal drip, but no nasal issues
Heartburn not always present
93
Why do we cough?
defense mechanism, clears pathogens, particulares, foreign bodies, and accumulated secretions from the lung airways, larynx, and pharynx
*For cough to effectively clear airway, both afferent and efferent pathways of cough reflex must be intact
94
Afferent pathway activation of cough
-which 3 types of nerves?
cough initiated in areas supplied by vagus nerve (or voluntarily by cerebral cortex)
1) Rapidly adapting receptors (RARs)
2) Slowly adapting stretch receptors (SARs)
3) C-fibers
95
Rapidly adapting receptors (RARs) and Slowly adapting stretch receptors (SARs)
highly sensitive to mechanical stimulation (bronchial obstruction, lung inflation)
96
C-fibers
highly sensitive to noxious chemical stimuli
97
Efferent pathway of cough (4 phases)
1) Inspiratory phase
2) Compressive phase
3) Expiratory phase
4) Relaxation phase
98
Inspiratory phase of cough
inhalation ends before closure of glottis
99
Compressive phase of cough
thoracic and abdominal muscles contract against a fixed diaphragm (e.g. Valsalva) → intrathoracic pressure increases
100
Expiratory phase of cough
glottis opens, air rapidly expelled
101
Relaxation phase of cough
chest wall and abdominal muscles relax
102
Acute cough
lasts less than 3 weeks
| -identify if life threatening or not
103
Life threatening causes of acute cough
pneumonia, severe asthma or COPD, pulmonary embolism, heart failure
104
Non-life threatening causes of acute cough
1) Infectious: URI or acute bronchitis (LRI)
2) Exacerbations of pre-existing condition (Asthma, brochiectasis, UACS, COPD)
3) Environmental/Occupational exposure to allergens (pollen, fungi, etc.) and irritants (chemicals, dust)
105
Upper respiratory tract infection (URI)
-treatment?
“common cold” (nasal congestion, discharge, sneezing)
-postnasal drip irritates larynx --> cough
→ Do not treat with abx (viral, e.g. rhinoviruses)
-Can use decongestants and cough suppressants
106
Lower respiratory tract infection (Acute bronchitis)
- 90% viral etiology
- Cough with or without sputum
- Distinguish from pneumonia with CXR (no infiltrates)
Treatment:
- antitussives/support
- NO ABX
- ABX if pertussis (whooping cough) or mycoplasma/ chalmydophila pneumonia
107
Subacute cough
-causes?
lasts 3-8 weeks
Post-infectious:
- Pneumonia
- Pertussis
- Bronchitis
- New onset exacerbation of UACS, Asthma, GERD, Bronchitis
Non-post infectious --> treat as chronic cough
108
Four most common causes of chronic cough
1) Upper Airway Cough Syndrome
2) Asthma
3) GERD
4) Non-Asthma Eosinophilic Bronchitis
109
Upper Airway Cough Syndrome (UACS)
-mechanism of cough production?
most common cause of chronic cough (postnasal drip syndrome)
Mechanism: stimulation of upper airway cough receptors by secretions from nose/paranasal sinuses → direct irritation/inflammation of upper airway cough receptors
110
Signs and Symptoms of UACS
Symptoms: “tickle” or something in throat, throat clearing, hoarseness, nasal congestion and drainage, inflamed nasal mucosa, secretions in posterior oropharynx
Signs: cobblestone oropharyngeal mucosa
111
Treatment of UACS
first gen antihistamine/ decongestant combination med for more than 2 weeks
112
Asthma
-mechanism of cough production?
chronic inflammatory disorder with variable airflow obstruction and airway hyperresponsiveness
Mechanism: stimulation of cough receptors by inflammatory mediators, mucus, bronchoconstriction
113
Signs and Symptoms of asthma?
Symptoms:
intermittent wheezing, dyspnea, cough
Cough variant asthma = cough is only symptom
Signs: bilateral, expiratory wheezing (when present)
> 12% and 200ml increase in FEV1 after SABA
Methacholine inhalation challenge positive (20% decline in lung function with low dose of methacholine)
114
GERD
mechanism of cough production (3)
backflow of stomach contents into esophagus
Mechanism: stimulation of afferent cough reflex by irritation of:
1) upper respiratory tract
2) lower respiratory tract (by aspiration of gastric contents)
3) Esophagus (esophageal-bronchial cough reflex, esophagus alone triggers cough)
115
Signs and Symptoms of GERD
Symptoms: cough with/without phlegm, heartburn, regurgitation, hoarseness (edema and erythema of larynx), sour taste in mouth (cough may be only symptom!)
Signs: none
116
Diagnosis of GERD
24 hr esophageal pH monitoring, esophagram
117
Treatment of GERD
gastric acid suppression with a proton pump inhibitor for > 2 months + diet and lifestyle modification
118
Non-Asthmatic Eosinophilic Bronchitis (NAEB)
Mechanism of cough stimulation?
-eosinophilic airway inflammation similar to asthma, but WITHOUT variable airflow limitation or airway hyperresponsiveness
Mechanism: stimulation of lower airway cough receptors by inflammatory mediators
119
Signs and symptoms of NAEB
Symptoms: cough without wheezing or dyspnea
Signs: no wheezing, normal PFTs methacholine challenge
-Induced sputum analysis shows >3% increase in eosinophils
120
Treatment of NAEB
inhaled corticosteroid for more than 4 weeks
121
Neuropathic Cough, aka Chronic Cough Hypersensitivity Syndrome
Cough triggered by low level stimuli - change in ambient temp, taking a deep breath, etc.
Caused by neural injury from: virus infection, chronic irritation/inflammation, or environmental pollutants
122
Differences of cough in children
Most common cause of cough is URI of viral etiology
Chronic cough = cough lasting > 4 weeks
-Common causes: asthma, sinusitis, GERD, inhaled foreign body, cystic fibrosis, second hand tobacco smoke
123
4 sites of action of antihistamines
1) H1 receptor blockade (reversible, competitive)
2) Muscarinic receptor block
3) Sodium channel block
4) Adrenergic (a1) receptor block
124
Effects of Muscarinic receptor block by histamines (3)
1) CNS side effects
2) prevent nausea and vomiting
3) block secretions --> Side effects: no pee, no see, no spit, no shit (urinary retention, blurred vision, dry mouth, constipation)
2nd generation do NOT block muscarinic receptors
125
Effects of sodium channel blockade by histamines (1)
1) local anesthetic effects
126
Effect of adrenergic (a1) receptor block by histamines (1)
1) may cause orthostatic hypotension
127
H1 receptor activation --> (5)
1) Vasodilation (endothelial cells)
2) Increased capillary permeability (endothelial cells)
3) GI smooth muscle contraction (Cramping)
4) Bronchoconstriction (bronchiolar smooth muscle)
5) Stimulate sensory nerve endings (pain, itching)
128
Treatment of common cold
1st gen antihistamine/decongestant (brompheniramine/pseudoephedrine)
+ Naproxen (anti-inflammatory cough suppression)
129
Treatment of UACS
1st gen antihistamine/decongestant (brompheniramine/pseudoephedrine)
130
Treatment of NAEB
inhaled corticosteroid
131
Treatment of neuropathic cough
Amitriptyline-Gabapentin
132
Pathophysiology of the common cold
Typically Rhinoviruses → attachment of virus to respiratory cells → inflammation (BRADYKININ release) → symptoms
1) Pain via nociceptors
2) Nasal stuffiness via dilation of blood vessels
3) Nasal fluid hypersecretion via increased capillary permeability
4) Cough via activation of irritant sensory receptors
* Mast cell mediators (histamine) only MINOR role in viral inflammatory response
133
4 names of first gen antihistamines
Meclizine
Dimenhydrinate
Bronpheniramine
Diphenhydramine (Benadryl)
134
First generation antihistamines:
Mechanism?
Kinetics?
Mechanism: H1 receptor antagonist
-Also blocks muscarinic, Na-channel and adrenergic receptors
Kinetics:
- Oral (rapid)
- Last 6-8 hours
* *CNS penetration
- CYP3A4 metabolized
135
Major clinical uses of first gen antihistamines (Meclizine/ Dimenhydrinate/Bronpheniramine/ Diphenhydramine) (5)
```
Allergic rhinitis
Anaphylactic reaction
Motion sickness
Insomnia
Cough suppression
```
136
Side effects of first gen antihistamines (Meclizine/ Dimenhydrinate/Bronpheniramine/ Diphenhydramine) (5)
M3 (muscarinic) block → SEDATION, antiemetic, blurred vision, DRY MOUTH, urinary retention
Na channel block → mild decrease in pain, cough
Adrenergic block → ORTHOSTATIC HYPOTENSION
Possible DDIs (CYP3A4 induction)
Chronic use may diminish effect → switch classes
137
3 names of 2nd gen antihistamines
Loratadine (Claritin)
Fexofenadine
Cetirizine
138
2nd gen antihistamine:
Mechanism?
Pharmacokinteics?
Mechanism: H1 histamine receptor antagonist ONLY and NOT in brain
Pharmacokinetics:
- Oral (rapid)
- Metabolised by liver (CYP3A4)
- 12-24 hour duration ** longer than first gen
- Decreased CNS penetration **no sedation, dry mouth, etc.
139
Major clinical uses of 2nd gen antihistamines
allergic rhinitis
140
Side effects of 2nd gen antihistamines (3)
```
Mild sedation
Possible DDIs (CYP3A4 induction)
Chronic use may diminish effect → switch classes
```
141
2 names of topical decongestants
Phenylephrine
| Oxymetazoline (Afrin)
142
2 names of oral decongestants
pseudoephedrine (Sudafed)
| phenylephrine (Sudafed PE)
143
Topical decongestants
benefits
Side effects
fast acting, no 1st pass metabolism
Side effects: possible rebound congestion with overuse because it’s so good at helping symptoms
144
Oral decongestants
benefits
side effects
longer acting
Affects other vessels to cause headache, dizziness, nervousness, increase BP, palpitations
145
Decongestants (oral and topical)
Mechanism of action
Clinical use
Mechanism of Action: stimulate alpha-1 adrenergic receptors, promoting vasoconstriction
→ drainage, improves breathing
Clinical Use: allergic rhinitis AND viral rhinitis
146
2 names of antitussive agents
codeine (hydrocodone)
| Dextromethorphan (Robitussin)
147
Codeine:
- Clinical use
- Mechanism of action
Clinical use: oral cough suppressant associated with cold symptoms, allergic rhinitis, asthma, and COPD
*Controlled substance, must be prescribed
Mechanism of action: binds mu-opioid receptors to suppress cough
148
Side effects of Codeine (3)
nausea, drowsiness, constipation
149
Dextromethorphan (Robitussin)
Clinical use?
Mechanism of action
oral cough suppressants
Most commonly used antitussive
Mechanism of action: binds mu-opioid receptors to suppress cough
150
Dextromethorphan (Robitussin)
side effects (2)
drowsiness, GI upset
Can have PCP (phencyclidine) effects at high (50-100x) doses = “Robo-Tripping” via block of NMDA glutamate receptors
151
Diphenhydramine (clinical use, mechanism, side effects)
Oral cough suppressants
Mechanism of action: H1 receptor antagonist
Side effects: sedation, antimuscarinic effects
152
Benzonate (Tessalon Perles) (clinical use, mechanism)
Oral cough suppressant
Mechanism of action: Tetracaine = local anesthetic to numb the throat
153
Expectorants (Guaifenesin)
- Oral
- Thought to stimulate secretions in respiratory tract to make more viscous and easier to clear
- Highly controversial, debatable efficacy → increasing fluid intake or using mist/vaporizer probably more effective
154
Guaifenesin Clinical uses and side effects (1)
Clinical uses: encourage ejection of phlegm/sputum → viral cold infections, COPD
Side effects: GI upset
155
Mucolytics: N-Acetylcysteine
mechanism of action
splits disulfide bonds to make mucous less viscous
156
Mucolytics: N-Acetylcysteine
adverse reactions
may trigger bronchospasm in COPD (give with dilator)
157
Mucolytics: N-Acetylcysteine
Clinical uses
viral cold infections, COPD
**Inhaled
158
Defense mechanisms of the lung (3)
1) Configuration of the nasopharynx and serial branching of airways ---> particle deposition proximal to more vulnerable alveolar structures
2) Mucociliary clearance and cough
3) Alveolar clearance (macrophages + immune response)
159
Mucociliary clearance and cough (4)
Large particles (>10um) deposited on mucous coated surfaces of airways
Mucous projected towards pharynx by beating of cilia on epithelial cells
Cleared by coughing, sneezing, and/or swallowing
Part of innate immune system
160
Problems with mucociliary clearance can result from... (3)
1) hypersecretion of mucous → chronic bronchitis, COPD, asthma, cystic fibrosis
2) Reduced clearance (air pollution, viral infection, cigarette smoke)
3) Abnormal ciliary function: Primary ciliary dyskinesia (immotile ciliary syndrome)
161
Abnormal ciliary function: Primary ciliary dyskinesia (immotile ciliary syndrome)
AR, defect in dynein arm
→ Sinusitis, bronchiectasis, situs inversus, infertility
Kartagener’s syndrome: situs inversus + chronic sinusitis + bronchiectasis
162
Discrimination between harmful and harmless material done by... (3)
1) Size and physiochemical property discrimination
2) Presence/Absence of PAMPs
3) Recognition by dendritic cells
163
If a PAMP is present then...
Presence of PAMP → activation of innate immunity → stimulate epithelial cells to express chemokines, cytokines, and lipid mediators → recruit neutrophils → DCs traffic to lymph nodes and stimulate T cell proliferation → alveolar macrophages initiate inflammation
164
If a PAMP is absent then...
-don't want to be reacting to everything we breathe in
→ DC cell recognizes it promotes anti-inflammation and tolerance to common antigens
- inflammation suppressed via tonic signaling of resident alveolar macrophages
- SIRPa bound to lung specific surfactant proteins (SP-A, SP-D) on alveolar macrophage
--> inhibition of NF-KB --> suppress inflammation in absence of PAMPs
165
How are microbes recognized by resident macrophages? (2)
1) Secreted pattern recognition receptors
| 2) Cellular pattern recognition receptors
166
Immune cells in pulmonary airspaces (normal vs. smoker)
Normal: 90-85% macrophages, 5% lymphocytes, 1% eosinophils, 1% neutrophils
Smokers → dramatically increase number of alveolar macrophages, change CD4/CD8 T cell ratio
167
Immune cell progression over time
1) Neutrophils
2) Monocytes/Macrophages
3) Lymphocytes
168
Neutrophils in lung defense
immediate effector cell
Attracted to lung by chemotactic factors produced by alveolar macrophages and epithelium (IL-8)
Ingest bacteria and fungi that have been opsonized by complement
-Kill by antioxidant production, microbial-cidal proteins and extracellular traps
169
Moncytes/Macrophages in lung defense (5)
1) Suppress pro-inflammatory adaptive immune responses
2) Clear particles, pathogens, apoptotic cells, and cellular debris
3) Elicit inflammatory response when appropriate (tonic state vs. presence of PAMPs)
- Alternatively programmed macrophages may generate inflammation that can be harmful (e.g. sarcoidosis, pulmonary fibrosis)
4) Induction of tissue cell repair
5) Activated by PAMPs
170
Resident alveolar macrophages vs. recruited monocytes/macrophages
Born with resident alveolar macrophages (from yolk sac and fetal liver), but can call upon migrating monocytes during infection
171
Adaptive immune response in the lung
B and T cells
Activated by exposure of DCs to PAMPs and antigens
Provides antigen specificity
Upon re-exposure, immunological memory allows for a more rapid and augmented secondary immune response
172
Primary TB infection
Initial infection by Mycobacterium tuberculosis (MTB)
Almost always occurs through the respiratory tract
In immunocompetent individuals, most primary infections do not develop into active disease → latent TB infection, infection cleared spontaneously, or active TB infection (immunocompromised)
173
Stage 1 of TB infection
ingestion by resident alveolar macrophages → necrotic death of macrophage → MTB survives and is released extracellularly and taken up by other macrophages
174
Stage 2 of TB infection
symbiotic stage
-MTB multiplies and macrophages accumulate
Monocytes migrate from blood into lungs → differentiate to macs
→ continued ingestion but no destruction of MTB
→ MTB multiples within inactivated macrophages
→ formation of early primary tubercle
175
Stage 3 of TB infection
migration of T cells to site of infection
T cells begin to activate macrophages to kill and prevent spread of MTB
Granulomas form (MTB unable to multiple within solid caseous material) → infection contained
In AIDS patients granulomas break down → reactivation
176
Stage 4a of TB infection
LTBI cellular level
Solid caseous center remains intact
Any bugs that escape ingested by highly activated macrophages
LTBI established if caseation remains solid and does not liquify
177
Stage 4b of TB infection
Decline in immunity → reactivation of TB
Immunosuppression (AIFS, cancer, anti-TNFa, aging, malnutrition)
→ Loss of integrity of granuloma
→Liquefaction of caseous material (“caseous necrosis”) provides favorable medium for MTB multiplication
→ Cavity forms → rupture and spread to other parts of lung and to other individuals
178
Latent TB infection:
CXR
PPD
Symptoms?
Virus?
1) CXR may show Ranke complex = calcified regional hilar and/or mediastinal lymph nodes + calcified lung nodules (Ghon complex)
- May also have a normal CXR
2) Asymptomatic
3) Positive PPD
4) Not shedding virus
179
Active TB infection
CXR
PPD
Symptoms?
Virus?
1) abnormal CXR with pneumonia +/- cavitary lesions
2) Symptomatic
3) Shedding virus
4) Positive PPD
180
Disadvantages of TB skin test
1) must wait 48-72 hours to read test
2) Can be false positive with BCG vaccination
3) False negativity in people with T cell depletion (AIDS, organ transplant)
4) Not very high sensitivity and specificity
181
A TB test is considered positive for who if the induration is >5mm? (5)
1) Recent close contact to an active case of TB
2) HIV positive
3) Apical fibronodular disease consistent with old healed TB
4) Organ transplant
5) Anti-TNFa therapy
182
A TB test is considered positive for who if the induration is >10mm? (4)
1) Recent TB skin test converter
2) Immigrants from high prevalent regions for TB
3) Other high risk groups (homeless, jail, healthcare workers)
4) Certain predisposing medical conditions (diabetes, dialysis, etc.)
183
A TB test is considered positive for who if the induration is >15mm?
All others - low risk people that shouldn't have been tested in the first place probably
184
IFNy release assay TB tests (2)
1) Quantiferon test
| 2) T-spot test
185
Quantiferon test
blood + antigens specific for MTB → measure IFNy by ELISA
Specifically tests for antigens of MTB, so can differentiate between those who have TB and those who were just vaccinated
186
T-spot TV test
assay of IFNy release, each spot = “footprint” of one IFNy producing cell
Better for detection in immunocompromised host
187
Benefits of IFNy assay TB tests (3)
1) More sensitive and specific than TST
2) Better positive predictive value than TST for a BCG-vaccinated person
3) Only one visit required
188
BCG scar vs. small pox scar?
BCG scar is raised
| Smallpox scar is sunken
189
3 options for treatment of latent TB:
1) 9 months Isoniazid (INH) daily or twice weekly (BIW)
- Risk of INH associated hepatitis
2) Rifampin daily for 4 months (fewer serious adverse events, better adherence, more cost effective than 9 months on INH)
3) INH + rifampin daily x 3 months ** the best option
190
What's the link between vitamin D and latent TB reactivation in recent immigrants
Vitamin D: suppresses growth of MTB in macrophages
191
Hypoxemic respiratory failure
inadequate oxygenation
O2 sat less than 87% or PaO2 less than 55
192
Common causes of hypoxemic respiratory failure? (5)
1) Impaired gas diffusion - Alveolar filling (Left HF with pulmonary edema, pneumonia, alveolar hemorrhage, ARDS)
2) Pulmonary vascular disease
3) V/Q mismatch (shunt, dead space)
4) Alveolar hypoventilation
5) High altitude with low inspired O2
193
Hypercapnic Respiratory Failure
elevated CO2, or any process that impairs ventilation (can't breathe or won't breathe)
194
Typical causes of "Can't Breathe" in hypercapnic respiratory failure
physiological hypoventilation
Asthma, COPD, upper airway obstruction, severe burn (chest wall restriction), neuromuscular
195
Typical causes of "Won't Breathe" in hypercapnic respiratory failure
central hypoventilation
Respiratory drive issues, over sedation, brain injury, seizure
196
Equation for acute respiratory acidosis and change in pH and [HCO3-]
increase PaCO2 by 10 mmHg → increase [HCO3-] by 1 mEq/L
Change in pH = 0.008 x (35-PaCO2)
In Denver, where normal CO2 = 35 mmHg
197
Equation for chronic respiratory acidosis and change in pH and [HCO3-]
increase PaCO2 by 10 mmHg → increase [HCO3-] by 4 mEq/L
Change in pH = 0.003 x (35-PaCO2)
In Denver, where normal CO2 = 35 mmHg
198
How to determine if respiratory acidosis is acute or chronic?
Change in pH/change in pCO2 → either 0.008 (acute) or 0.003 (chronic)
Somewhere in between? → acute on chronic
199
standard notation of ABGs
pH/CO2/pO2
200
Determinants of ventilation (2)
1) Respiratory Rate
2) Tidal volume
*adjust in case of hypercapnic respiratory failure
201
Determinants of oxygenation (4)
1) FIO2
2) Positive End Expiratory Pressure (PEEP)
*adjust in case of hypoxemic respiratory failure
202
Positive end-expiratory pressure (PEEP)
- used to achieve and maintain alveolar recruitment by limiting lung deflation at end expiration
- Determinant of oxygenation
-Without PEEP patients can develop atelectasis (deflation of alveoli)
→ decreases effective alveolar/capillary surface area
Diffusion capacity and oxygenation directly proportional to SA available for gas exchange
**Used to maintain surface area in hypoxemia: more PEEP, more recruitment (up to a point)
203
4 defining characteristics of ARDS
1) Diffuse bilateral pulmonary infiltrates
2) Occurs within one week of known clinical insult or worsening respiratory symptoms
3) Not fully explained by cardiac failure or fluid overload
4) PaO2/FIO2 ratio less than 300
204
Most common causes of ARDS (5)
sepsis, pancreatitis, trauma, aspiration, transfusion (also fat embolism, amniotic fluid embolism)
205
Severity of ARDS classified by PaO2/FIO2 with > 5 cm H2O PEEP:
mild, moderate, and severe
PaO2/FIO2 = 201-300 → mild, 27% mortality
PaO2/FIO2 = 101-200 → moderate, 32% mortality
PaO2/FIO2 = less than 100 → severe, 45% mortality
206
Pathogenesis of ARDS
- alveolar inflammation with increased permeability of pulmonary capillaries and recruitment of inflammatory cells (PMNs, cytokines)
- Loss of alveolar/capillary barrier function
- Loss of surfactant (increased intraalveolar fluid)
207
Histopathology of ARDS
1) “hyaline membrane” formation
2) neutrophil influx
3) hemorrhage
4) type II cell hyperplasia
5) alveolar filling with proteinaceous edema
6) systemic inflammation often with extrapulmonary organ dysfunction or failure
208
Treatment strategies to improve survival in ARDS (4)
1) Treat underlying cause of ARDS
2) Supportive care
3) Prone positioning in severe disease
4) Ventilator management
209
Best ventilator management
survival advantage in ARDS patients ventilated with tidal volumes of 6cc/kg vs. 12cc/kg
Ventilator Induced Lung Injury → high tidal volume ventilation can worsen lung injury and systemic inflammation in ARDS patients
**before increasing a patient’s tidal volume based on ABG analysis, make certain that the patient does not meet criteria for ARDS - could be detrimental to patient
210
Major determinants of site and severity of lung disease (3)
1) Dose = duration x concentration
2) Solubility
3) Particle size
211
Effect of solubility on severity of lung disease
More water soluble → deposit in upper airway
Less water soluble → affect distal airways/bronchioles
212
Effect of particle size on severity of lung disease
Particles > 10 microns → ?
Particles less than 10 microns → ?
Particles less than 2.5 microns → ?
Particles > 10 microns → filtered by upper airway
Particles less than 10 microns → respirable, penetrate deeply into lung
Particles less than 2.5 microns → affect small airways and alveoli
213
What is the most important tool for evaluating occupational lung disease?
OCCUPATIONAL HISTORY
(chronology of jobs, location, name, years of employment)
```
job titles
specific exposures
specific duties
use of PPE
similar symptoms in co workers
```
214
Two major categories of occupational lung disease
1) Airways diseases (obstructive)
| 2) Interstitial diseases (restrictive)
215
Four types of airways disease
1) Occupational Asthma (immunologic)
2) Irritant Asthma aka Reactive Airways Dysfunction Syndrome (RADS)
3) Occupational Emphysema/COPD
4) Bronchiolitis (obstructive/constrictive)
216
Occupational (Immunologic) Asthma
Presentation
Causes
**Isocyantaes (spray paint/autobody painting)
**Onset may be months to years after initial exposure
*Isocyanate exposure → new onset respiratory symptoms → high index of suspicion for occupational asthma
217
Irritant asthma (Reactive Airways Dysfunction Syndrome, RADS)
Causes
Presentation
Causes: **Strong acids and bases (e.g. alkaline world trade center dust)
Presentation: **NO LATENCY - symptom onset within 24-48 hours of exposure
218
Occupational Emphysema/COPD is typically caused by...
coal mine dust
| silica (sand blasting)
219
Five types of ILD
Pneumoconioses:
1) Asbestos related lung disease
2) Silicosis
3) Coal workers pneumoconiosis (black lung)
Other ILDs:
4) Chronic beryllium disease
5) Hypersensitivity Pneumonitis (Farmer's Lung)
220
Asbestos related lung disease
exposed groups?
signs on CXR?
Exposed groups: construction workers, shipyard/dock workers, mechanics
Malignant (mesothelioma)
**Non-malignant asbestos-related lung disease → pleural effusion, pleural thickening/calcifications/plaques
**CXR with PLEURAL PLAQUES → ASBESTOS
(WILL BE ON TEST)
221
Silicosis
causes
presentation
Progressive, massive fibrosis
**Causes: mining, foundry work, sandblasting, oil and gas industry workers
Presentation: long latency (unless high-grade exposure), cough, SOB
222
Chronic beryllium disease
*Granulomatous lung disease (indistinguishable from sarcoidosis) except that it is due to exposure and subsequent immune response to beryllium
223
In regards to PIO2, what changes occur at high altitude
Higher altitude → lower barometric pressure
i. PB on everest is 253 → PaO2 = 25 mmHg → SaO2 = 50%
ii. Compared to PB of 630 in Denver and 760 and sea level
224
Acute ventilator and cardiac compensation to high altitude (3)
Minutes-> hours
1. Increase CO, increase HR
2. Increase VE (hyperventilation → decrease PaCO2)
a. MOST USEFUL short term adaptive response to high altitude (increases hemoglobin saturation)
3. Decrease SVR - systemic and brain vasodilation, pulmonary vasoconstriction ( → transient pulmonary HTN
225
Chronic ventilator and cardiac compensation to high altitude (5)
1. Increase VE (chronic reduced PaCO2 levels)
2. Increase [Hb] - increase EPO, increase RBC mass (increase O2 carrying capacity)
3. Structural change in Hb → altered affinity for O2 and left shift due to respiratory alkalosis → increases Hb O2 saturation
4. Increase CO2 ventilatory response
a. Acclimatized individuals have augmented hypoxic drive to breathe
5. Increase capillary density and myoglobin in muscles
226
Adaption to high altitude
genetic event that occurs over generations
1.Maximizes delivery of oxygen to tissues
227
Major illnesses associated with high altitude (4)
1. Acute mountain sickness
2. High altitude cerebral edema (HACE)
3. High altitude pulmonary edema (HAPE)
4. Chronic Mountain Sickness (CMS)
228
Acute mountain sickness
1. Headache + at least 2 other symptoms after rapid ascent (fatigue/weakness, insomnia, poor appetite/nausea, malaise)
2. Common at CO ski resorts
3. “Tight box theory” - brain edema with hypoxia due to increased cerebral blood flow in restrictive box (skull)
229
Treatment of acute mountain sickness
Symptoms usually resolve in uncomplicated AMS without treatment, can use analgesics to help headache
Symptomatic AMS → oral dexamethasone (corticosteroid) or oral acetazolamide (diuretic that causes respiratory alkalosis)
230
Prevention of acute mountain sickness
a. Start day before, continue 1-2 days after ascent to high altitude
b. Acclimatize at lower altitude first!
c. Dexamethasone → steroid that blunts hypoxic induction of brain vessel permeability-inducing proteins
d. Acetazolamide → bicarbonate diuresis → metabolic acidosis) → increase VE → respiratory alkalosis
e. Ibuprofen → decrease headache
231
High altitude cerebral edema
severe AMS, medical emergency
1. Uncommon, but can recur so pt must avoid altitude
2. AMS with ataxia or mental status change
232
Treatment of HACE
Supportive: oxygen, descent, mechanical ventilation
b.IV dexamethasone
233
High altitude pulmonary edema
noncardiogenic pulmonary edema, life-threatening form of AMS
1. +/- signs of AMS
2. Exuberant pulmonary HTN in response to acute hypoxia, lung capillary breakdown, with plasma/blood leakage into alveoli
a. People who increase their pulmonary artery pressures more than others with exercise are more prone to HAPE
234
Symptoms of HAPE
onset on 2nd day at altitude, rapid progression
a. Cough (pink frothy sputum)
b. SOB
c. Fatigue
d. Hypoxia, rales, infiltrates
235
Treatment of HAPE
a. Immediate descent, supplemental O2
b. Vasodilators (lower PAP) - nifedipine, sildenafil, tadalafil
c. NOT DIURETICS
236
Prevention of HAPE
a. Avoid high altitude
b. Pulmonary vasodilators (nifedipine, Tadalafil/Sildenafil)
c. Bronchodilatory, LABA (salmeterol) - increases clearance of water out of alveoli
d. Dexamethasone
237
Chronic Mountain Sickness
polycythemia + pulmonary HTN/RV failure
1. Occurs at > 10,000 feet
2. Increase risk of stroke and heart failure
3. Poor concentration
4. Infants → lower birth weights, higher mortality, mothers also have increased rates of preeclampsia
238
Diseases that cause problems at high altitude (3)
i. Lowered PaO2 at rest: Lung disease (not asthma), CHF, hypoventilation
ii. Limited minute volume: COPD, pulmonary fibrosis, morbid obesity
iii. Existing pulmonary HTN or left heart failure
239
Clinical Syndromes Associated with Diving/Breath holding/Compressed gas breathing: (4)
1. Pulmonary barotrauma
2. decompression sickness (bends)
3. Nitrogen narcosis
4. Shallow water blackout
240
Pulmonary barotrauma
increased pressure in airways can lead to extravasation of air along bronchial tree → Pneumomediastinum, Pneumothorax, Air embolism
241
Pulmonary barotrauma is more common in (3)
a. Asthma increases risk of barotrauma because alveolar units that exhale more slowly expand and rupture during ascent
b. Anyone with lung blebs/cysts
c. Free dives (single breath, quick/deep)
242
Decompression sickness
occurs with too rapid an ascent
1.Gas in supersaturated tissues can form bubbles as pressure decreases with surfacing → bubbles expand in tissues/blood causing organ dysfunction
243
Symptoms of decompression sickness
confusion, MSK pain, dyspnea, stroke, coma, seizures, paralysis, death
244
Treatment of decompression sickness
recompression or hyperbaric chamber) to drive gases back into dissolved state
245
Nitrogen narcosis
occurs when diver breathes compressed air (>79% N2) at depths > 100 ft → increased N2 in tissues (including brain)
246
Symptoms and treatment of nitrogen narcosis
Symptoms: bizarre behavior, unconsciousness, euphoria, confusion
2.Use helium at dives > 100 ft
247
Shallow water blackout
hyperventilate to increase PaO2, and blow down PaCO2 before submerging → hypoxemia causes unconsciousness before dyspnea occurs
248
Physics of diving
increase pressure with depth
1. Lungs and the air in them are compressed with dive
a. → increased density of gas due to compression → **increased resistive work of breathing
b. → problem for people with existing airflow limitation (COPD, moderate/mild asthma exacerbation)
2. Increased blood return to lungs (from squeezed limbs/abd) → decreased compliance, → increase in CO and central filling pressures
a. increased pressure = decreased volume
b. “Squeeze” = tissues displaced into space gas occupied at surface
c. → Heart failure patients should avoid diving
3. Increased depth = increased dissolved gases in tissues
a. Inert gases (N2, helium) can form bubbles
249
Differences between adult and pediatric pulmonary physiology (3)
1) Infant’s larynx and trachea are significantly smaller than an adult
2) Children have weaker muscles and different anatomy
3) Pediatric signs of respiratory distress are different
250
Size of pediatric vs. adult airway
Infant’s larynx and trachea are significantly smaller than an adult
Narrowest part of pediatric airway just below vocal cords at level of cricoid cartilage (only complete ring of cartilage)
Narrowest part in adults is vocal cords
Decreases in airway radius results in significant increase in resistance and reduction in cross sectional area of pediatric airway
251
Differences between adult and children pulmonary anatomy (5)
1) Children have weaker muscles (flat diaphragm, weak intercostals)
2) Larynx higher and more anterior
3) Epiglottis is floppy, large, touching soft palate
4) infants primarily breath through nose (facilitate suck/swallow/breathe)
5) Tongue is relatively large
252
Pediatric signs of respiratory distress (4)
1) Lethargy
2) poor feeding
3) grunting
4) trouble gaining weight (due to chronic respiratory disease causing increased work of breathing)
253
Signs/Symptoms of upper respiratory airway obstruction (5)
Stridor
+ 4 D’s of SEVERE obstruction = drooling, dysphagia, dyspnea/distress
NOT hypoxemia (because if you do, then it is because you are hypoventilation, and that is really bad)
254
Laryngomalacia is the most common cause of _______ due to a problem during the _______ phase that causes what?
chronic stridor
Embryonic phase
→ cartilaginous support for supraglottic structures is underdeveloped
255
Clinical features of laryngomalacia
- Extrathoracic obstruction
- Usually presents by 6 weeks
- Worse with eating, crying, activity
- Better prone
- Often outgrown by 1-2 years old
- If severe, requires surgery
- Can cause OSA
256
Tracheobronchomalacia is caused by a problem in the _______ stage resulting in what?
pseudoglandular stage (wk 6-16)
Intrathoracic obstruction
Cartilage of trachea is extra soft and collapses with expiration → problem with breathing out
257
Symptoms of tracheobronchomalacia
Recurrent wheeze and hoarse, wet cough, recurrent illness
258
Viral croup is the most common cause of...
Typically caused by what virus?
acute airway obstruction in children
Inflammation of entire airway and edema in subglottic space (larynx)
parainfluenza
259
Symptoms of viral croup (4)
1) Barking cough
2) Stridor
3) *Fever (typically low grade)
4) *Cough in ABSENCE OF DROOLING favors dx of viral croup over epiglottitis
260
Epiglottitis
Almost always caused by H. influenzae B
Inflammation and swelling of supraglottic structures (epiglottis, arytenoids) can develop rapidly and lead to life-threatening upper airway obstruction
261
Signs/Symptoms of epiglottitis (5)
Sudden onset of:
1) high fever
2) dysphagia
3) drooling
4) inspiratory retractions
5) cyanosis
262
Bacterial tracheitis
severe, life-threatening form of viral croup
Usually viral infection --> bacterial infection caused by staph aureus
Localized mucosal invasion of bacteria in patients with primary viral croup → inflammatory edema, purulent secretions, pseudomembranes
263
Signs/symptoms of bacterial tracheitis
1) usually older kids
2) high fever
3) normal epiglottis with copious purulent tracheal secretions
4) unresponsive to croup therapy
264
Bronchiolitis is the most common cause of...
typically caused by what virus?
lower airway obstruction
RSV
265
Why is bronchiolitis worse in kids that are premature?
Premature kids →
1) decreased SA for gas exchange --> increased need for O2
2) thickened interstitium → decreased compliance → more significant complications
266
Signs/Symptoms of bronchiolitis in kids
1) expiratory wheezing and crackles
2) acute onset tachypnea (rapid, shallow respirations)
3) retractions (to increase TV)
4) Grunting (attempt to keep airways open)
5) fever
6) hyperinflation
267
Asthma in kids
#1 reason for peds ER visits and hospitalizations
90% of the time is allergic
Diagnosis:
Recurrent symptoms of airway obstruction (cough, SOB, chest tightness)
Partial reversal of bronchospasm/symptom relief with bronchodilator
268
Treatment of bacterial pneumonia in children:
0-3 months
3 months-5 years
> 5 years
0-3 months → IV ampicillin or aminoglycosides + hospital admission
3 month-5 years → oral amoxicillin
>5 yrs → macrolide, amoxicillin or penicillin G
269
Bronchopulmonary dysplasia
ARDS in first weeks of life --> decreased surface area for gas exchange
- require O2 and mechanical ventilation
- can cause persistent respiratory abnormalities
270
Vicious cycle of bronchopulmonary dysplasia
```
Insufficient functional surfactant
+ Insufficient antioxidant defense mechanisms
+ Structural immaturity
+ Atelectasis
+ Pulmonary edema
```
--> require mechanical ventilation
BUT mechanical ventilation can make this all worse
271
Long term complications of bronchopulmonary dysplasia (4)
1) Abnormal oxygenation and ventilation at baseline
2) Trouble with viral illness or exercise
3) Possible need for oxygen/ventilation long term
4) Limited activity
272
Findings in children with cystic fibrosis (7)
1) Greasy, bulky, malodorous stools
2) Failure to thrive
3) Focal sclerosis in liver
4) Failure of vas deferens to develop
5) Recurrent respiratory infectious (bronchiectasis, bronchiolitis)
6) Digital clubbing on exam
7) Sweat chloride > 60 mmol/L
